KILITCH vs LUPIN: Stock Comparison

Kilitch Drugs (India) Limited vs Lupin Limited

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Lupin Limited is the larger company by market capitalisation. Kilitch Drugs (India) Limited shows a lower P/E and faster revenue growth, while Lupin Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Kilitch Drugs (India) Limited and Lupin Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KILITCH is more favourable on 4 of 13 scored metrics and LUPIN on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LUPIN is the larger company
₹1.1 L Cr vs ₹617 Cr
P/E Ratio
KILITCH has a lower P/E
20.92x vs 21.56x
P/B Ratio
KILITCH has a lower P/B
2.26x vs 5.12x
EPS
LUPIN has higher earnings per share
₹116.56 vs ₹8.92
Dividend Yield
LUPIN has a higher dividend yield
0.48% vs 0%
Revenue Growth (TTM YoY)
KILITCH has faster revenue growth
46.3% vs 31.9%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs 26.5%
Qtr Sales Growth
LUPIN has stronger quarterly sales growth
31.9% vs 29%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKILITCHLUPIN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKILITCHLUPIN
Live Price₹196.99₹2,407.5
Day Change-4.15%-4.27%
Volume1.36 L10.61 L
52-Week High₹439₹2,529.5
52-Week Low₹117.25₹1,836.8
Distance from 52W High-55.13%-4.82%

Valuation

MetricKILITCHLUPIN
Market Cap₹617 Cr₹1.1 L Cr
P/E Ratio20.92x21.56x
P/B Ratio2.26x5.12x
EPS₹8.92₹116.56
Book Value₹81.67₹491.29
Dividend Yield0%0.48%

Growth

MetricKILITCHLUPIN
Revenue Growth (TTM YoY)46.3%31.9%
EPS Growth (TTM YoY)26.5%89%
Qtr Sales Growth29%31.9%
Qtr Profit Growth126%101%

Profitability & Leverage

MetricKILITCHLUPIN
ROE12.36%29.1%
ROCE15.7%30.3%
Net Margin12.81%17.65%
Operating Margin14%31.5%
Debt to Equity32.04x0.29x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKILITCHLUPIN
Promoter Holding63.77%46.57% 0.04 pp
FII Holding0.12% 0.12 pp21.71% 0.22 pp
DII Holding0%25.32% 0.26 pp
Public Holding36.11% 0.11 pp6.11% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Kilitch Drugs (India) Limited and Lupin Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.